Computed Tomography-Guided Interstitial HDR Brachytherapy (CT-HDRBT) of the Liver in Patients with Irresectable Intrahepatic Cholangiocarcinoma

Journal Article · Fri Jun 15 04:00:00 EDT 2012 · Cardiovascular and Interventional Radiology

DOI:https://doi.org/10.1007/S00270-011-0249-0· OSTI ID:21608515

Schnapauff, Dirk; Denecke, Timm; Grieser, Christian; Colletini, Federico ^[1]; Seehofer, Daniel ^[2]; Sinn, Marianne ^[3]; Banzer, Jan; Lopez-Haenninen, Enrique; Hamm, Bernd ^[1]; Wust, Peter ^[4]; Gebauer, Bernhard ^[1]

---

1. Charite, Universitaetsmedizin, Department of Radiology (Germany)
2. Charite, Universitaetsmedizin, Department of Surgery (Germany)
3. Charite, Universitaetsmedizin, Department of Hematology/Oncology (Germany)
4. Charite, Universitaetsmedizin Berlin, Department of Radiation Oncology (Germany)

Purpose: This study was designed to investigate the clinical outcome of patients with irresectable, intrahepatic cholangiocarcinoma (IHC) treated with computed tomography (CT)-guided HDR-brachytherapy (CT-HDRBT) for local tumor ablation.MethodFifteen consecutive patients with histologically proven cholangiocarcinoma were selected for this retrospective study. Patients were treated by high-dose-rate internal brachytherapy (HDRBT) using an Iridium-192 source in afterloading technique through CT-guided percutaneous placed catheters. A total of 27 brachytherapy treatments were performed in these patients between 2006 and 2009. Median tumor enclosing target dose was 20 Gy, and mean target volume of the radiated tumors was 131 ({+-} 90) ml (range, 10-257 ml). Follow-up consisted of clinical visits and magnetic resonance imaging of the liver every third month. Statistical evaluation included survival analysis using the Kaplan-Meier method. Results: After a median follow-up of 18 (range, 1-27) months after local ablation, 6 of the 15 patients are still alive; 4 of them did not get further chemotherapy and are regarded as disease-free. The reached median local tumor control was 10 months; median local tumor control, including repetitive local ablation, was 11 months. Median survival after local ablation was 14 months and after primary diagnosis 21 months. Conclusion: In view of current clinical data on the clinical outcome of cholangiocarcinoma, locally ablative treatment with CT-HDRBT represents a promising and safe technique for patients who are not eligible for tumor resection.

• OSTI ID: 21608515
• Journal Information: Cardiovascular and Interventional Radiology, Journal Name: Cardiovascular and Interventional Radiology Journal Issue: 3 Vol. 35; ISSN 0174-1551; ISSN CAIRDG
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ABLATION
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
BRACHYTHERAPY
CHEMOTHERAPY
COMPUTERIZED TOMOGRAPHY
CONTROL
DAYS LIVING RADIOISOTOPES
DIAGNOSIS
DIAGNOSTIC TECHNIQUES
DIGESTIVE SYSTEM
DISEASES
DOSE RATES
DOSES
ELECTRON CAPTURE RADIOISOTOPES
EVALUATION
GLANDS
HEAVY NUCLEI
INTERNAL CONVERSION RADIOISOTOPES
IRIDIUM 192
IRIDIUM ISOTOPES
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
LIVER
MEDICINE
MINUTES LIVING RADIOISOTOPES
NEOPLASMS
NMR IMAGING
NUCLEAR MEDICINE
NUCLEI
ODD-ODD NUCLEI
ORGANS
PATIENTS
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
THERAPY
TOMOGRAPHY
YEARS LIVING RADIOISOTOPES